Elmalky, Mahmoud, Yasin, Naveed, Rodrigues-Pinto, Ricardo, Stephenson, John, Carroll, Craig, Smurthwaite, Glyn, Verma, Rajat, Mohammad, Saeed and Siddique, Irfan

The safety, efficacy and cost-effectiveness of intraoperative cell-salvage in metastatic spine tumour surgery

Original Citation


This version is available at http://eprints.hud.ac.uk/id/eprint/31755/

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

http://eprints.hud.ac.uk/
Title: The safety, efficacy and cost-effectiveness of intraoperative cell-salvage in metastatic spine tumour surgery

Author: Mahmoud Elmalky, Naveed Yasin, Ricardo Rodrigues-Pinto, John Stephenson, Craig Carroll, Glyn Smurthwaite, Rajat Verma, Saeed Mohammad, Irfan Siddique

PII: S1529-9430(17)30091-8
DOI: http://dx.doi.org/doi: 10.1016/j.spinee.2017.03.004
Reference: SPINEE 57258

To appear in: The Spine Journal

Received date: 30-6-2016
Revised date: 9-2-2017
Accepted date: 15-3-2017


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Title: The safety, efficacy and cost-effectiveness of intraoperative cell-salvage in metastatic spine tumour surgery

Authors: Mahmoud Elmalky¹,⁴, MD (Tr & Orth); Naveed Yasin¹, FRCS (Tr & Orth); Ricardo Rodrigues-Pinto¹,², MD, PhD; John Stephenson³, PhD CMath MIMA FRSS; Craig Carroll¹, FRCA; Glyn Smurthwaite¹, FRCA; Rajat Verma¹, FRCS (Tr & Orth); Saeed Mohammad¹, FRCS (Tr & Orth); Irfan Siddique¹, FRCS (Tr & Orth)

Institutions:
1) Department of Spinal Surgery
   Salford Royal Hospital NHS Foundation Trust
   Stott Lane, Lancashire, M6 8HD
   United Kingdom

2) Department of Orthopaedics
   Centro Hospitalar do Porto – Hospital de Santo António
   Largo Prof. Abel Salazar
   4099-001 Porto
   Portugal

3) School of Human and Health Sciences
   University of Huddersfield, Queensgate
   Huddersfield HD1 3DH
   United Kingdom

4) Department of Orthopaedics
   Menoufia University,
   Shibin Al Kawm
   Egypt

Corresponding author:
Mr. Mahmoud Elmalky
Department of Spinal Surgery
Salford Royal Hospital NHS Foundation Trust
Stott Lane, Lancashire, M6 8HD
United Kingdom
mah_elmalky@yahoo.com
Tel: 00447450277337

ABSTRACT

Background context: Metastatic spine tumour surgery (MSTS) is associated with substantial blood loss therefore leading to high morbidity and mortality. While intraoperative cell salvage with leucocyte depletion filter (IOCS-LDF) has been studied as an effective mean of reducing blood loss in other surgical settings, including the spine, no study has yet analysed the efficacy of re-infusion of
salvaged blood in reducing the need for allogenic blood transfusion in patients who have had surgery for MSTS.

**Purpose:** To analyse the efficacy, safety and cost effectiveness of using IOCS-LDF in MSTS.

**Study design/ Setting:** Retropective controlled study

**Patient sample:** 176 patients undergoing MSTS

**Methods:** All patients undergoing MSTS at a single centre between February 2010 and December 2014 were included in the study. The primary outcome measure was the use of autologous blood transfusion. Secondary outcome measures included hospital stay, survival time, complications and procedural costs. The key predictor variable was whether or not IOCS-LDF was utilised during surgery. Logistic and linear regression analyses were conducted by controlling variables such as tumour type, number of diseased vertebrae, approach, number and site of stabilised segments, operation time, pre-operative anaemia, ASA grade, age, gender and BMI. No funding was obtained and there are no conflicts of interest to be declared.

**Results:** Data included 63 cases (IOCS-LDF) and 113 controls (non IOCS-LDF). IOCS-LDF utilisation was substantively and significantly associated with a lower likelihood of allogenic blood transfusion (OR=0.407, p=0.03). IOCS-LDF was cost neutral (p=0.88). Average hospital stay was 3.76 days shorter amongst IOCS-LDF patients (p=0.03). Patient survival and complication rates were comparable in both groups.

**Conclusions:** We have demonstrated that the use of IOCS-LDF in MSTS reduces the need for post-operative allogenic blood transfusion whilst maintaining satisfactory post-operative haemoglobin. We recommend routine use of IOCS-LDF in MSTS for its safety, efficacy and potential cost benefit.

**Keywords:** "intraoperative cell salvage", "intraoperative blood salvage autotransfusion", "autologous transfusion", "autotransfusion", "malignant tumour", "tumour surgery", "cell saver", "blood loss in spinal metastatic surgeries, and "leucocyte depletion filter"
INTRODUCTION

Metastatic spine tumour surgery (MSTS) aims to decompress neural structures, preserve cord function, stabilise the spine and confirm diagnosis prior to further oncological treatment. Whilst recent advances in perioperative care, spinal instrumentation and surgical techniques have led to improved clinical outcomes in MSTS, the peri-operative and postoperative risks remain high.[1, 2] Surgical treatment of MSTS is often associated with substantial blood loss and need for autologous blood transfusion, both of which contribute to high morbidity and potential mortality associated with these surgeries. In a meta-analysis published in 2013, Chen et al[3] found a mean blood loss of 2180ml in spinal tumour surgeries with a possibility of catastrophic blood loss of more than 5000ml in 12% of patients.[3]

A number of peri- and intra-operative strategies exist to reduce the risk of blood loss. Their aim is to minimize the need for allogeneic blood product transfusion, decrease total blood loss, and reduce cost.[4] Additionally, they maintain high/adequate post-operative haemoglobin which potentially benefits patient recovery and could affect postoperative complication rates.[5]

Intraoperative cell salvage (IOCS) involves the collection of shed surgical blood, filtration, and reinfusion to the patient and reduces the need of allogeneic blood transfusion.[6] It has been demonstrated to be a viable option for reduction or avoidance of allogeneic blood product during many oncologic surgeries and may be a lifesaving option for patients who refuse allogeneic blood products.[7]

The use of IOCS has been investigated in other oncological surgeries. In gynaecology, hepatic, urological and cardiothoracic setting it has been demonstrated as being safe and efficacious in reducing allogeneic blood transfusion.[6-8]

Although IOCS provides benefits, it carries some risks. In paediatric patients transient haematuria, concern for reinfusion of heparinized blood leading to altered haemostasis and alteration in electrolyte balance have been reported. Furthermore, IOCS is potentially costly, and requires additional personnel intraoperatively.[7]
In oncological surgeries, efficacy of using the leucocyte depletion filter (LDF) to remove malignant
cells from intra-operative cell salvage blood has been studied in vitro and in vivo and reported as a
potentially safe.[9] Previous studies have also evaluated the effectiveness of using IOCS with LDF to
eliminate tumour cells from salvaged blood in spinal tumour surgeries[10, 11]. However no large
scale comparative studies have been published to evaluate the efficacy in reducing the need for
autologous blood transfusion or cost effectiveness in spinal tumour surgery.[12]

In a systematic review published in 2014, Kumar et al suggested that the evidence base [10, 11] in
other oncological surgeries would support the use of IOCS in MSTS but recognised the lack of
evidence in this particular patient group.[12]

The aim of this study was to evaluate the safety, efficacy and cost effectiveness of IOCS in MSTS.

METHODS

Data was retrospectively obtained from studying all patients undergoing MSTS at a single tertiary
referral centre between February 2010 and December 2014. Case notes and electronic inpatient
hospital records were reviewed. All disease related, patient related, surgery related and post-operative
charts were reviewed to complete the data.

Logistic and linear regression analyses were conducted, considering whether or not an allogenic blood
transfusion was given and post-operative haemoglobin levels as primary outcome measures.

Secondary outcome measures included length of stay, post-operative survival time, complications and
procedural costs. The key predictor variable was whether or not IOCS-LDF was utilised during the
surgical procedure.

A number of procedural-related, health-related and demographic variables were also initially
considered as controlling variables for the primary analyses. Procedural-related variables were: type
of tumour (categorised as thyroid/renal or non-thyroid/renal); number of vertebrae (affected spinal
levels in the operative field); anatomical region (cervical, cervicothoracic, thoracic, thoracolumbar or
lumbar); approach (posterior, anterior or combined); number of stabilised spinal levels and operation
time. Health-related variables were: pre-operative anaemia and ASA (American Society of
Anaesthesiologists) grade. Demographic variables were: age; gender and body mass index (BMI).

Data was summarised descriptively. Exploratory procedures were undertaken to assess data distributions, extent of missing data and possible collinearity. Logistic regression analyses were conducted using the allogenic blood transfusion outcome measure. A sequential modelling strategy was utilised with the key predictor variable of IOCS-LDF utilisation included at the highest level of the model hierarchy. All procedural-related variables were then fitted at the second stage of the hierarchy. Health-related variables, ASA grade and anaemia status were fitted at the third level of the hierarchy. Demographic variables of age, gender and BMI were fitted at the fourth (lowest) level of the hierarchy. For hierarchical levels 2-4, stepwise routines were utilised to derive an optimum selection of variables within the level. Final model adequacy was assessed using Nagelkerke’s pseudo-$R^2$ statistic, and the percentage of cases correctly classified by the model was evaluated.

Linear regression analyses were conducted on the data using the post-operative haemoglobin level outcome measure utilising the same sequential modelling strategy as for the sequential logistic regression modelling. Cross-validation and diagnostic procedures were conducted on both of the final logistic and linear regression models.

Secondary outcomes were assessed using descriptive and univariable methods. Association between IOCS-LDF group and patient survival was assessed using the $\chi^2$ test for association. Associations between IOCS-LDF group, length of hospital stay and total procedural costs were assessed using independent samples t-test.

Cost calculation was performed analysing the combined cost of use of IOCS-LDF equipment and cost of allogenic blood.

RESULTS
Analysis was conducted on 176 patients, from an original dataset of 178 patients. Two patients were not assigned to an IOCS-LDF group and were excluded from the analysis. Less than 0.5% of the remaining data in total was missing, and imputation methods were not used.

Data comprised 63 cases (use of IOCS-LDF) (35.8% of valid cases) and 113 controls (no use of IOCS-LDF) (64.2% of valid cases). Dataset included 106 males (60.2%) and 70 females (39.8%); with a mean age of 63.2 years (SD 12.6 years) (Table 1).

Exploratory analyses indicated evidence for collinearity effects between certain variables necessitating the removal of variables corresponding to number of affected vertebrae and anatomical region from subsequent analyses.

**Analysis of need for allogenic blood transfusion outcome**

Using the stepwise modelling strategy within each level of a sequential logistic regression procedure, the Level-2 variable corresponding to approach and stabilised levels entered the model at the 2nd step, following the forced entry of the key predictor variable of IOCS-LDF at step 1. No other variables were included in the model at this step. Both Level-3 variables (ASA grade and preoperative anaemia) were included in the model at the 3rd step. None of the Level-4 variables (demographic variables) were included in the model at the 4th step. Hence, the final model included the variables IOCS-LDF, approach, number of stabilised levels, ASA grade and preoperative anaemia (Table 2).

IOCS-LDF was found to be substantively and significantly associated with this outcome, as were number of stabilised levels, anaemia status and ASA grade. Approach was substantively associated with the need for allogenic blood transfusion but did not achieve statistical significance at the 5% level.

Controlling for other variables, the odds of a patient receiving an allogenic blood transfusion were 59% higher in cases where IOCS-LDF was not utilised than when it was utilised. A higher probability of allogenic blood transfusion was found in patients whose procedures involved anterior, rather than posterior approach (not statistically significant), greater extents of spinal fixation, higher ASA grades (indicating worse morbidity) and preoperative anaemia.
Nagelkerke’s pseudo-$R^2$ statistic for the parsimonious model was 0.276, indicating that the model is a good fit to the data. The model correctly classified 73.4% of cases in the sample. A model derived from a training set comprising 80% of cases correctly classified 70.0% of cases in a validation set comprising the remaining 20% of the sample; indicating good predictive capability. Studentised residuals and Cook’s distances were within expectations for all cases, indicating that no data point exerts excessive influence on the model.

**Analysis of post-operative haemoglobin outcome**

Using the stepwise modelling strategy within each level of a sequential regression procedure, the Level-2 variable corresponding to stabilised levels entered the model at the second step, following the forced entry of the key predictor variable of IOCS-LDF at step 1. The Level-3 variable corresponding to anaemia entered the model at the 3rd step. The Level-4 demographic variable gender was included in the model at the 4th step. Hence the final model included the variables IOCS-LDF, stabilised levels, anaemia and gender (Table 3).

While the controlling variables corresponding to number of stabilised levels, anaemia and gender were found to be significantly associated with the outcome, the IOCS-LDF variable did not achieve statistical significance at the 5% level, or appear to show any substantive importance. Higher post-operative haemoglobin levels were found in patients whose procedures involved lesser extents of spinal fixation, in those without anaemia and in males. Controlling for other variables, an increase of one stabilised level was associated with a decreased post-operative haemoglobin count of 1.55 units; pre-operatively anaemic patients had 6.9 units post-operative haemoglobin count less than non-anaemic patients; and male patients had 8.7 units post-operative haemoglobin count greater than female.

The adjusted (Wherry) $R^2$ value for the final model was 0.111. Stein’s adjusted $R^2$ statistic for the final model was 0.0863; indicating an adequately performing model with good cross validity predictive power. Studentised residuals and Cook’s distances were within expectations for all cases, indicating that no data point exerts excessive influence on the model. No evidence for violation of
regression assumptions was detected during residual analysis procedures: residuals were found to be
normally distributed and homogeneity of variance was achieved.

Analyses of secondary outcomes
The association between patient survival and IOCS-LDF was not significant using a $\chi^2$ test for
association ($\chi^2(1)=0.245; p=0.620$). Length of stay was 3.76 days shorter on average amongst those
for whom IOCS-LDF was utilised (15.9 days) than amongst those for whom IOCS-LDF was not
utilised (19.1 days). This difference was statistically significant using an independent samples t-test
($p=0.028$). A 95% confidence interval for the difference was given by (0.34, 6.01).

IOCS-LDF costs £128.41 per case. The cost of the allogenic blood is £135.7 for a red blood cell unit,
£215.03 for a platelets unit and £29.11 for a unit of fresh frozen plasma. The total procedural cost for
patients for whom cell salvage was utilised and for whom IOCS-LDF was not utilised was not
significantly different using an independent samples t-test ($p=0.875$).

No difference in the peri and post-operative complications was found between the two groups.

DISCUSSION

Blood loss in MSTS is a major complication due to the tumour nature or altered spinal vascular
anatomy (dilated epidural veins, hypervascularity and neovascularisation). Controlling blood loss is
difficult. To date, very little evidence exists to support the use of IOCS-LDF in MSTS. [14-16]

Blood loss can affect patient recovery, delay wound healing and increase the risk of wound infection,
ultimately delaying further oncological (radio or chemotherapy) treatment, increasing hospital stay
and adding to healthcare costs.[17]

The evaluation of the efficacy of blood conservation techniques in MSTS is compounded by many
factors that can influence blood loss. These include type of primary tumour (non vascular/vascular),
number of affected segments, number of operated levels, operative time and approach. Additionally,
health related factors such as pre-operative anaemic status of the patients, ASA grading and BMI are
also variables that can potentially influence blood loss. This is, to our knowledge, the first study to comprehensively consider and control for these confounding factors in evaluating the use of IOCS-LDF in MSTS.

All of these factors have been previously demonstrated as potentially affecting blood loss; Zhenget al[18] reported the factors affecting blood loss and blood transfusion in patients having segmental spinal surgeries as number of levels fused, age, and low preoperative haemoglobin. Many studies have validated to role of BMI and ASA grade as factors which affect intraoperative blood loss. Therefore, in analysing the benefits of intraoperative cell salvage we have controlled for these potentially confounding factors in order to accurately establish the efficacy of IOCS-LDF in reducing the need for allogenic blood transfusion[19-23].

The choice of surgical approach is dependent upon the source of compression (anterior or posterior), patient comorbidity, associated deformity, surgeon’s experience and spinal instability. Cases with 3-column spinal disease, compression, deformity (kyphosis) and instability can require combined, anterior and posterior, decompression and stabilisation. These procedures are associated with significantly greater morbidity and blood loss, therefore have been controlled for in the analyses.[24-26]

To our knowledge, to date, no studies have analysed the cost-effectiveness of IOCS-LDF in MSTS. However, in liver transplant and hepatocellular carcinoma it has been found to be cost-effective.[27, 28]. Ubee etal [29] concluded that the cost benefits of IOCS make this technique economically efficient, clinically effective and an attractive alternative to other methods of transfusion for open radical prostatectomy surgery.[29] Our results show that using IOCS-LDF is potentially cost neutral. The total procedural cost for patients for whom IOCS-LDF was utilised and for whom IOCS-LDF was not utilised was found to be not significantly different. However our study did not include the additional staff cost that can be associated with use of IOCS-LDF.

The short hospital stay is an important focus of modern hospital management with associated reduction in cost and improvements the quality of health care. Our results show that using IOCS is consistent with a reduced hospital stay. Whilst this difference was observed and significant, it is likely that unmeasured factors, rather than the utilisation of IOCS-LDF, have contributed to this
finding (for example, patients’ neurological status). In our study no association was found between patient survival and IOCS-LDF.

Whilst our data was analysed retrospectively, missing data was minimal and with the substantial number of patients and an analysis that controls for the majority of the known and measurable confounding factors that can influence blood loss in this type of surgery, our findings would suggest that the routine use of IOCS-LDF in MSTS has clear benefits for both patients and healthcare providers.

The National Institute for Health and Care Excellence (NICE) published guidelines endorsing the use of IOCS-LDF for radical prostatectomy and cystectomy.[30] We would advise, based on our findings, the routine use of IOCS-LDF in MSTS.

CONCLUSION

In summary we have demonstrated that the use of IOCS-LDF in MSTS reduces the need for post-operative allogenic blood transfusion whilst maintaining satisfactory post-operative haemoglobin. The use of IOCS-LDF may be cost-effective depending on the personnel set-up. We would recommend routine use of IOCS-LDF in MSTS for its safety and efficacy.
DECLARATION OF INTERESTS

The authors declare they have no conflicts of interest related to this work.

RR-P was a recipient of a PhD grant from Programme for Advanced Medical Education, sponsored by Fundação Calouste Gulbenkian, Fundação Champalimaud, Ministério da Saúde, Fundação para a Ciência e Tecnologia and Apifarma, Portugal (between 2010 and 2014) and has undertaken a Fellowship supported by the Internation Group for the Advancement of Spinal Sciences in 2014, all outside the scope of the submitted work.
REFERENCES


Table 1: descriptive summary of cohort

<table>
<thead>
<tr>
<th>Variable</th>
<th>Cases (n=63)</th>
<th>Controls (n=113)</th>
<th>All patients (n=176)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males (frequency (valid %))</td>
<td>45 (71.4%)</td>
<td>61 (54.0%)</td>
<td>106 (60.2%)</td>
</tr>
<tr>
<td>Females (frequency (valid %))</td>
<td>18 (28.6%)</td>
<td>52 (46.0%)</td>
<td>70 (39.8%)</td>
</tr>
<tr>
<td><strong>Age (mean (SD))</strong></td>
<td>63.6 (13.8)</td>
<td>64.1 (11.5)</td>
<td>63.6 (12.6)</td>
</tr>
<tr>
<td><strong>BMI (mean (SD))</strong></td>
<td>25.9 (4.55)</td>
<td>25.7 (4.58)</td>
<td>25.8 (4.54)</td>
</tr>
<tr>
<td><strong>Number of affected vertebrae (median (range))</strong></td>
<td>1 (1-7)</td>
<td>1 (1-4)</td>
<td>1 (1-7)</td>
</tr>
<tr>
<td><strong>Number of stabilised levels (median (range))</strong></td>
<td>4 (2-12)</td>
<td>4 (0-11)</td>
<td>4 (0-12)</td>
</tr>
<tr>
<td><strong>Operation time (hours) (mean (SD))</strong></td>
<td>4.64 (1.66)</td>
<td>4.04 (1.54)</td>
<td>4.26 (1.62)</td>
</tr>
<tr>
<td><strong>ASA score (median (range))</strong></td>
<td>3 (1-5)</td>
<td>3 (1-5)</td>
<td>3 (1-5)</td>
</tr>
<tr>
<td><strong>Length of stay in days (mean (SD))</strong></td>
<td>15.9 (7.38)</td>
<td>19.1 (9.96)</td>
<td>17.9 (9.19)</td>
</tr>
<tr>
<td><strong>Type of tumour</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-thyroid/renal (frequency (valid %))</td>
<td>53 (86.9%)</td>
<td>105 (93.8%)</td>
<td>158 (91.3%)</td>
</tr>
<tr>
<td>Thyroid/renal (frequency (valid %))</td>
<td>8 (13.1%)</td>
<td>7 (6.2%)</td>
<td>15 (8.7%)</td>
</tr>
<tr>
<td><strong>Approach</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Posterior only (frequency (valid %))</td>
<td>51 (81.0%)</td>
<td>96 (85.0%)</td>
<td>147 (83.5%)</td>
</tr>
<tr>
<td>Anterior/both (frequency (valid %))</td>
<td>12 (19.0%)</td>
<td>17 (15.0%)</td>
<td>29 (16.5%)</td>
</tr>
<tr>
<td><strong>Level code</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical (frequency (valid %))</td>
<td>3 (4.8%)</td>
<td>11 (9.7%)</td>
<td>14 (8.0%)</td>
</tr>
<tr>
<td>Cervicothoracic (frequency (valid %))</td>
<td>7 (11.1%)</td>
<td>9 (8.0%)</td>
<td>16 (9.1%)</td>
</tr>
<tr>
<td>Thoracic (frequency (valid %))</td>
<td>28 (44.4%)</td>
<td>52 (46.0%)</td>
<td>80 (45.5%)</td>
</tr>
<tr>
<td>Thoracolumbar (frequency (valid %))</td>
<td>16 (25.4%)</td>
<td>35 (31.0%)</td>
<td>51 (29.0%)</td>
</tr>
<tr>
<td>Lumbar (frequency (valid %))</td>
<td>9 (14.3%)</td>
<td>5 (5.3%)</td>
<td>15 (8.5%)</td>
</tr>
<tr>
<td><strong>Preoperative anaemia</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No anaemia (frequency (valid %))</td>
<td>29 (46.0%)</td>
<td>58 (51.3%)</td>
<td>87 (49.4%)</td>
</tr>
<tr>
<td>Anaemia (frequency (valid %))</td>
<td>34 (53.0%)</td>
<td>55 (48.7%)</td>
<td>89 (50.6%)</td>
</tr>
<tr>
<td><strong>Surgical complications</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No complications (frequency (valid %))</td>
<td>59 (95.2%)</td>
<td>107 (99.1%)</td>
<td>166 (97.6%)</td>
</tr>
<tr>
<td>Complications (frequency (valid %))</td>
<td>3 (4.8%)</td>
<td>1 (0.9%)</td>
<td>4 (2.4%)</td>
</tr>
<tr>
<td><strong>Patient survival</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death recorded (frequency (valid %))</td>
<td>26 (41.3%)</td>
<td>51 (45.1%)</td>
<td>77 (43.8%)</td>
</tr>
<tr>
<td>No death recorded (frequency (valid %))</td>
<td>37 (58.7%)</td>
<td>62 (54.9%)</td>
<td>99 (56.2%)</td>
</tr>
<tr>
<td><strong>Procedural cost (mean (SD))</strong></td>
<td>GBP351.78</td>
<td>GBP338.42</td>
<td>GBP340.77 (GBP286.67)</td>
</tr>
</tbody>
</table>


Table 2: Parameter coefficients, confidence intervals and p-values of all variables included in final model (blood transfusion outcome measure)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Parameter estimate</th>
<th>Odds ratio (OR)</th>
<th>95% confidence interval for OR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IOCS-LDF</td>
<td>-0.898</td>
<td>0.407</td>
<td>(0.180, 0.920)</td>
<td>0.031</td>
</tr>
<tr>
<td>Approach¹</td>
<td>0.923</td>
<td>2.516</td>
<td>(0.866, 7.304)</td>
<td>0.090</td>
</tr>
<tr>
<td>Number of stabilised levels</td>
<td>0.408</td>
<td>1.503</td>
<td>(1.221, 1.852)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Anaemia status²</td>
<td>1.042</td>
<td>2.836</td>
<td>(1.337, 6.016)</td>
<td>0.007</td>
</tr>
<tr>
<td>ASA grade</td>
<td>0.806</td>
<td>2.239</td>
<td>(1.244, 4.031)</td>
<td>0.007</td>
</tr>
</tbody>
</table>

¹Reference category=posterior approach
²Reference category=no anaemia

Table 3: Parameter coefficients, confidence intervals and p-values of all variables included in final model (post-operative haemoglobin outcome measure)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unstandardised coefficient</th>
<th>95% confidence interval</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IOCS-LDF</td>
<td>-1.568</td>
<td>(-6.708, 3.572)</td>
<td>0.548</td>
</tr>
<tr>
<td>stabilised levels</td>
<td>-1.553</td>
<td>(-2.778, -0.328)</td>
<td>0.013</td>
</tr>
<tr>
<td>Anaemia</td>
<td>-6.892</td>
<td>(-11.81, -1.97)</td>
<td>0.006</td>
</tr>
<tr>
<td>Gender</td>
<td>-8.692</td>
<td>(-13.77, -3.61)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

¹Reference category=no anaemia
²Reference category=male